Patents by Inventor Andreas Ritzen

Andreas Ritzen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phenylimidazole derivative as PDE10A enzyme inhibitor
    Patent number: 8841297
    Abstract: This invention provides the compound 5,8-Dimethyl-2-[2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]thazolo[1,5-a]pyrazine and pharmaceutically acceptable acid addition salts thereof.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: September 23, 2014
    Assignee: H. Lundbeck A/S
    Inventors: Andreas Ritzén, Jan Kehler, Morten Langgård, Jacob Nielsen, John Paul Kilburn, Mohammed M. Farah
  • Substituted thiomorpholine derivatives
    Patent number: 8299075
    Abstract: The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: October 30, 2012
    Assignee: H. Lundbeck A/S
    Inventors: Christian Wenzel Tornoe, Mario Rottlander, Nikolay Khanzhin, William Patrick Watson, Andreas Ritzen
  • NOVEL PHENYLIMIDAZOLE DERIVATIVE AS PDE10A ENZYME INHIBITOR
    Publication number: 20120190685
    Abstract: This invention provides the compound 5,8-Dimethyl-2-[2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]thazolo[1,5-a]pyrazine and pharmaceutically acceptable acid addition salts thereof.
    Type: Application
    Filed: June 17, 2010
    Publication date: July 26, 2012
    Applicant: H. Lundbeck A/S
    Inventors: Andreas Ritzén, Jan Kehler, Morten Langgård, Jacob Nielsen, John Paul Kilburn, Mohammed M. Farah
  • NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS
    Publication number: 20120135987
    Abstract: This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.
    Type: Application
    Filed: February 3, 2012
    Publication date: May 31, 2012
    Applicant: H. Lundbeck A/S
    Inventors: Andreas Ritzén, Jan Kehler, Morten Langgård, Jacob Nielsen, John Paul Kilburn, Mohamed M. Farah
  • Phenylimidazole derivatives as PDE10A enzyme inhibitors
    Patent number: 8133897
    Abstract: This invention is directed to phenylimidazole compounds, which are PDE10A enzyme inhibitors useful for the treatment of neurological and psychiatric disorders.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: March 13, 2012
    Assignee: H. Lundbeck A/S
    Inventors: Andreas Ritzén, Jan Kehler, Morten Langgård, Jacob Nielsen, John Paul Kilburn
  • SUBSTITUTED THIOMORPHOLINE DERIVATIVES
    Publication number: 20110294787
    Abstract: The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.
    Type: Application
    Filed: July 28, 2011
    Publication date: December 1, 2011
    Applicant: H. Lundbeck A/S
    Inventors: Christian Wenzel Tornøe, Mario Rottländer, Nikolay Khanzhin, Andreas Ritzèn, William Patrick Watson
  • Substituted thiomorpholine derivatives
    Patent number: 8012962
    Abstract: The present invention relates to thiomorpholine derivatives of formula I or pharmaceutically acceptable salts thereof and their use in treating seizure disorders, anxiety disorders, bipolar disorders, neuropathic pain disorders and migraine pain disorders.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: September 6, 2011
    Assignee: H. Lundbeck A/S
    Inventors: Christian Wenzel Tornoe, Mario Rottlander, Nikolay Khanzhin, Andreas Ritzen, William Patrick Watson
  • Substituted p-diaminobenzene derivatives
    Patent number: 7906537
    Abstract: The present invention relates to aniline derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: March 15, 2011
    Assignee: H. Lundbeck A/S
    Inventors: Nikolay Khanzhin, Mario Rottlander, Andreas Ritzen, William P. Watson
  • Methods of using substituted morpholine derivatives
    Patent number: 7812023
    Abstract: The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: October 12, 2010
    Assignee: H. Lundbeck A/S
    Inventors: Christian Wenzel Tornøe, Mario Rottländer, Nikolay Khanzhin, Andreas Ritzèn, William Patrick Watson
  • SUBSTITUTED ANILINE DERIVATIVES
    Publication number: 20100063044
    Abstract: The present invention relates to aniline derivatives of formula I: wherein R1, R2, R3, R4, Z and q are as defined herein; or salts thereof and their use.
    Type: Application
    Filed: August 17, 2009
    Publication date: March 11, 2010
    Applicant: H. Lundbeck A/S
    Inventors: Christian Wenzel Tornoe, Mario Rottlãnder, Daniel Rodriguez Greve, Nikolay Khanzhin, Andreas Ritzén, William Patrick Watson
  • Methods of using substituted morpholine derivatives
    Publication number: 20100063033
    Abstract: The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.
    Type: Application
    Filed: November 5, 2009
    Publication date: March 11, 2010
    Inventors: Christian Wenzel Tornøe, Mario Rottländer, Nikolay Khanzhin, Andreas Ritzén, William Patrick Watson
  • Substituted morpholine and thiomorpholine derivatives
    Publication number: 20100063036
    Abstract: The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.
    Type: Application
    Filed: November 3, 2009
    Publication date: March 11, 2010
    Applicant: H. Lundbeck A/S
    Inventors: Christian Wenzel Tornøe, Mario Rottländer, Nikolay Khanzhin, Andreas Ritzén, William Patrick Watson
  • NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS
    Publication number: 20100016303
    Abstract: This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.
    Type: Application
    Filed: June 19, 2009
    Publication date: January 21, 2010
    Applicant: H. LUNDBECK A/S
    Inventors: Andreas Ritzén, Jan Kehler, Morten Langgård, Jacob Nielsen, John Paul Kilburn, Mohamed M. Farah
  • Substituted morpholine and thiomorpholine derivatives
    Patent number: 7632835
    Abstract: The present invention relates to morpholine and thiomorpholine derivatives or the general formula I or pharmaceutically acceptable salts thereof and their use.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: December 15, 2009
    Assignee: H. Lundbeck A/S
    Inventors: Christian Wenzel Tornoe, Mario Rottlander, Nikolay Khanzhin, Andreas Ritzen, William Patrick Watson
  • Substituted aniline derivatives
    Patent number: 7601870
    Abstract: The present invention relates to aniline derivatives of the general formula I or salts thereof, described therein, and their use.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: October 13, 2009
    Assignee: H. Lundbeck A/S
    Inventors: Christian Wenzel Tornøe, Mario Rottländer, Daniel Rodriguez Greve, Nikolay Khanzhin, Andreas Ritzén, William Patrick Watson
  • METHODS OF USING SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES
    Publication number: 20090143369
    Abstract: The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.
    Type: Application
    Filed: January 28, 2009
    Publication date: June 4, 2009
    Applicant: H. LUNDBECK A/S
    Inventors: Christian Wenzel Tornoe, Mario Rottlander, Nikolay Khanzhin, Andreas Ritzen, William Patrick Watson
  • SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES
    Publication number: 20090137571
    Abstract: The present invention relates to morpholine and thiomorpholine derivatives or the general formula I or pharmaceutically acceptable salts thereof and their use.
    Type: Application
    Filed: January 28, 2009
    Publication date: May 28, 2009
    Applicant: H. LUNDBECK A/S
    Inventors: Christian Wenzel Tornoe, Mario Rottlander, Nikolay Khanzhin, Andreas Ritzen, William Patrick Watson
  • USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA
    Publication number: 20090118285
    Abstract: The invention relates to a novel method for treating or reducing the symptoms of schizophrenia, said method comprising administering to a host in need thereof an effective amount of a compound able to selectively increase the ion flow through KCNQ potassium channels. Furthermore the invention relates to the use of selective KCNQ potassium channel openers for the preparation of a pharmaceutical composition for treating or reducing the symptoms of schizophrenia and related symptoms, disorders and diseases. Furthermore the invention relates to a method of screening for a compound, which is a selective KCNQ potassium channel opener and which is capable of having an anti-psychotic potential.
    Type: Application
    Filed: February 2, 2007
    Publication date: May 7, 2009
    Applicant: H. Lundbeck A/S
    Inventors: Henriette Husum Bak-Jensen, Christian Wenzel Tornoe, Mario Rottlander, Daniel Rodriguez Greve, Nikolay Khanzhin, Andreas Ritzen, William Patrick Watson
  • Substituted morpholine and thiomorpholine derivatives
    Patent number: 7501414
    Abstract: The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: March 10, 2009
    Assignee: H. Lundbeck A/S
    Inventors: Christian Wenzel Tornøe, Mario Rottländer, Nikolay Khanzhin, Andreas Ritzèn, William Patrick Watson
  • 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system
    Patent number: 7368472
    Abstract: The present invention concerns 1,2,4-triaminobenzene derivatives of the general formula I or pharmaceutically acceptable salts thereof and the use thereof.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: May 6, 2008
    Assignee: H. Lundbeck A/S
    Inventors: Mario Rottlander, Andreas Ritzen, Morten Bang Norgaard, Nikolay Khanzhin, Christian Wenzel Tornoe